Search hospitals
>
Delaware
>
Lewes
Beebe Medical Center
Claim this profile
Lewes, Delaware 19958
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Breast cancer
Conducts research for Ovarian Cancer
Conducts research for Cancer
269 reported clinical trials
2 medical researchers
Summary
Beebe Medical Center is a medical facility located in Lewes, Delaware. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Ovarian Cancer, Cancer and other specialties. Beebe Medical Center is involved with conducting 269 clinical trials across 398 conditions. There are 2 research doctors associated with this hospital, such as Gregory A. Masters and Mark E. Borowsky.
Area of expertise
Breast Cancer
Beebe Medical Center has run 57 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Beebe Medical Center has run 50 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Gregory A. Masters
Helen F Graham Cancer Center
7 years of reported clinical research
Mark E. Borowsky
Jersey Shore Medical Center
6 years of reported clinical research
Clinical Trials running at Beebe Medical Center
Lung Cancer
Breast Cancer
Prostate Cancer
Breast cancer
Cancer
Colorectal Cancer
Esophageal cancer
Ovarian Cancer
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
High-Dose Radiation + Chemotherapy and Immunotherapy
for Non-Small Cell Lung Cancer
This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.
Recruiting
2 awards
Phase 3
14 criteria
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting
2 awards
Phase 3
4 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Beebe Medical Center?
Beebe Medical Center is a medical facility located in Lewes, Delaware. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Ovarian Cancer, Cancer and other specialties. Beebe Medical Center is involved with conducting 269 clinical trials across 398 conditions. There are 2 research doctors associated with this hospital, such as Gregory A. Masters and Mark E. Borowsky.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.